We are monitoring the impact of COVID-19 on Histone Deacetylase Inhibitors Market Get in touch with us for detailed analysis Know More
Pulished Date April, 2021
ID: 5286
Share on
Share on

Global Histone Deacetylase (HDAC) Inhibitors Market Size, Share, Trends & Growth Analysis Report – Segmented By Class, Application & Region - Industry Forecasts (2021 to 2026)

Pulished: April, 2021
ID: 5286
Pages: 175

Global Histone Deacetylase Inhibitors Market Size (2021 to 2026):

As per our research report, the size of the global histone deacetylase inhibitors market to worth USD 152 Million by 2026, growing at a CAGR of 8.11% from 2021 to 2026.

Histone Deacetylase Inhibitors are classified in the product such as DEAE-Dextron, calcium phosphate, Activated dendrimers, etc., and the equipment-liposomes, microinjection, and laserfection. HDACs play an important role in the regulation of gene expression. HDACs are present in a high amount in many types of tumor.

MARKET DRIVERS:

The adoption of innovative technology advancements, improvements in the healthcare infrastructure, and the rapid growth rate in government initiatives in pharmaceutical & biotechnology companies for the drug developments greatly influence the global histone deacetylase inhibitors market growth.

Collaborations between the companies & lunch of innovative products are increasing the growth of the market. An increase in cancer patients and other illnesses with effective results in treatment is driving the market of HDAC market. Investment in research and development activities surges the market. HDAC reduces the rate of angiogenesis & sincreases the immune response, providing scope for market growth.

A growing number of people suffering from cancer is a crucial factor propelling the market demand. Increasing support from the government and the rise in investments in research and development in the cancer treatment field drive the demand of the market. Huge demand for achieving maximum productivity with very less cost is the major factor responsible for boosting up the market growth. The manufacturers of histone deacetylase inhibitors collaborate with other companies, which is also one of the factors leading to market growth. 

Need to make better changes in the effectiveness of new treatments, growing mergers and collaborations also accelerate market growth. The rise in the common increase of cancer is also bolstering the market. Also, research and development related to disorders or nerves and other diseases are driving the market forward. Funds from the government and other organizations are also boosting the market. Pharmaceutical industries spending huge amounts of money on R&D and growing prevalence for diagnosing the disease at an early stage are ascribed to bolster the market's growth rate. 

MARKET RESTRAINTS:

Lack of reimbursement policies in undeveloped countries is hindering the global Histone deacetylase inhibitors market growth.

Lack of knowledge among the people may limit the growth rate of this market. Strict rules and guidelines to be followed for the product to be approved are also the factors that restrain the market growth. Less awareness in the patients for the treatment of cancer & chronic diseases are hampering the market growth. The rising value of raw material required for the production & manufacturing of HDACs has reduced the market growth for the future. HDACs side effects such as toxicity after consumption are also a factor impeding the demand of the market. Some factors that influence the HDACs market are less skilled professionals in well-developed countries.

Impact of COVID-19 on the global histone deacetylase inhibitors market:

The novel coronavirus (COVID 19) has strained severe health risks to humans and the economy. By March 2020, the virus has spread to every country across the globe. In general, HDAC inhibitors are used by kidney and diabetic patients to fight the disease-causing cells. The use of HDAC inhibitor, romidepsin, effectively stops the virus from entering the body. The U.S Food and Drug Administration (FDA) approves HDAC inhibitors treatment for pulmonary fibrosis and essential molecular mechanisms in executing the pathological procedures in recovered COVID 19 patients. Panobinostat is one HDAC inhibitor that can act as a preventive drug against COVID 19. HDAC presents one of the most promising viral drugs used in treating the infectious virus. As of now, six HDAC anticancer drugs were approved by the FDA. In the current situations, the EMA-approved SARS-CoV-2 off-labeled HDAC inhibitor drugs are reused to restrain or avoid the host-virus interaction. The HDAC valproic acid, which is available for treating those who are diagnosed with epilepsy. The drug is remodeled for patients with COVID 19 to avoid acute respiratory distress syndrome (ARDS). The valproic acid helps both COVID-19 infection and in those who are infected decreases the ARDS along with other aimed organ damage, reducing hospitalizations and death. 

REPORT COVERAGE:

REPORT METRIC

DETAILS

Market Size Available

2021 to 2026

Base Year

2020

Forecast Period

2021 to 2026

Segments Covered

By Class, Application, and Region

Various Analyses Covered

Global, Regional & Country Level Analysis, Segment-Level Analysis, Drivers, Restraints, Opportunities, Challenges, PESTLE Analysis, Porter’s Five Forces Analysis, Competitive Landscape, Analyst Overview on Investment Opportunities

Regions Covered

North America, Europe, Asia Pacific, Latin America, Middle East & Africa

 

This market research report on Global Histone Deacetylase Inhibitors Market has been segmented based on class, application, and region.

Histone Deacetylase Inhibitors Market - By Class:

  • Class I HDACs
  • Class II HDACs
  • Class III HDACs

Histone Deacetylase Inhibitors Market – By Application:

  • Cancer
  • Central Nervous System Disorders

Histone Deacetylase Inhibitors Market – By Region:

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • The Middle East and Africa

Geographically, the North American regional market accounted for the largest share in the global market. It is expected to retain its lead by 2025. Higher adoption rates in this region are the cause attributable to the observable trend mentioned above. Europe comes second by market share. It is, however, anticipated to experience slow growth in the forecast period. 

Europe stands second, followed by North America. This region is likely to have a high CAGR value during the period and is estimated to reach a million-dollar USD. In the European region, the UK is expected to lead the market. The adoption of advanced technology in the healthcare centers is propelling the demand of the market.

The Asia Pacific is poised for a robust growth trajectory in the forecast period. China will spearhead this growth spurt. Latin America and MEA continue to tail these leading regional markets in the forecast period.

KEY MARKET PARTICIPANTS:

Some of the notable companies leading the global histone deacetylase inhibitors market profiled in the report are Merck & Co., Inc., Celgene Corporation, Eisai Pharmaceuticals, Novartis, Acetylon Pharmaceuticals, Celeron Therapeutics, Envivo Pharmaceuticals, and Pfizer, Inc.

RECENT MARKET DEVELOPMENTS:

  • On November 29, 2019, the Shenzhen Chipscreen Biosciences Company. Ltd. launched an innovative product named Epidaza (Chidamide), it's an oral subtype of histone deacetylase inhibitors. This product is used for the treatment of HER2- advance negative breast cancer. Shenzhen had received approval from the National Medical Products Administration.
  • On November 19, 2019, Alkermes, the Irish biopharmaceutical company,, announced Rodin Therapeutic's acquisition of worth US $ 950million. Rodin Therapeutics developed the small molecule therapy for synaptopathy. They also designed the molecules to target the histone deacetylase inhibitors. Inhibition decreases the toxicity of haematologic safety.

1. Introduction        

                1.1 Market Definition                    

                1.2 Study Deliverables                  

                1.3 Base Currency, Base Year and Forecast Periods 

                1.4 General Study Assumptions                

2. Research Methodology                  

                2.1 Introduction      

                2.2 Research Phases                      

       2.2.1 Secondary Research           

       2.2.2 Primary Research 

       2.2.3 Econometric Modelling      

       2.2.4 Expert Validation  

                2.3 Analysis Design

                2.4 Study Timeline 

3. Overview              

                3.1 Executive Summary                

                3.2 Key Inferences

                3.3 Epidemiology     

4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)           

                4.1 Market Drivers 

                4.2 Market Restraints                    

                4.3 Key Challenges

                4.4 Current Opportunities in the Market     

5. Market Segmentation                     

                5.1 Class     

       5.1.1 Introduction           

       5.1.2 Class I HDACs         

       5.1.3 Class II HDACs        

       5.1.4 Class III HDACs       

       5.1.5  Y-o-Y Growth Analysis, By Class    

       5.1.6  Market Attractiveness Analysis, By Class  

       5.1.7  Market Share Analysis, By Class    

                5.2 Application                 

       5.2.1 Introduction           

       5.2.2 Cancer      

       5.2.3 Central Nervous System Disorders               

       5.2.4 Other Diseases      

       5.2.5 Y-o-Y Growth Analysis, By Application         

       5.2.6 Market Attractiveness Analysis, By Application 

       5.2.7 Market Share Analysis, By Application        

6. Geographical Analysis                     

                6.1 Introduction      

       6.1.1 Regional Trends    

       6.1.2 Impact Analysis     

       6.1.3 Y-o-Y Growth Analysis        

                       6.1.3.1 By Geographical Area

                       6.1.3.2 By Class

                       6.1.3.3 By Application

       6.1.4  Market Attractiveness Analysis     

                       6.1.4.1 By Geographical Area

                       6.1.4.2 By Class

                       6.1.4.3 By Application

       6.1.5  Market Share Analysis      

                       6.1.5.1 By Geographical Area

                       6.1.5.2 By Class

                       6.1.5.3 By Application

                6.2 North America

       6.2.1 Introduction           

       6.2.2 United States         

       6.2.3 Canada     

                6.3 Europe                         

       6.3.1 Introduction           

       6.3.2 U.K             

       6.3.3 Spain         

       6.3.4 Germany 

       6.3.5 Italy            

       6.3.6 France       

                6.4 Asia-Pacific                 

       6.4.1 Introduction           

       6.4.2 China         

       6.4.3 India          

       6.4.4 Japan         

       6.4.5 Australia   

       6.4.6 South Korea           

                6.5 Latin America    

       6.5.1 Introduction           

       6.5.2 Brazil          

       6.5.3 Argentina

       6.5.4 Mexico     

       6.5.5 Rest of Latin America          

                6.6 Middle East & Africa      

       6.6.1 Introduction           

       6.6.2 Middle-East            

       6.6.3 Africa         

7. Strategic Analysis              

                7.1 PESTLE analysis

       7.1.1 Political     

       7.1.2 Economic 

       7.1.3 Social         

       7.1.4 Technological         

       7.1.5 Legal          

       7.1.6 Environmental       

                7.2 Porter’s Five analysis     

       7.2.1 Bargaining Power of Suppliers        

       7.2.2 Bargaining Power of Consumers    

       7.2.3 Threat of New Entrants     

       7.2.4 Threat of Substitute Products and Services 

       7.2.5 Competitive Rivalry within the Industry     

8. Market Leaders' Analysis               

                8.1 Celgene                       

       8.1.1 Overview 

       8.1.2 Product Analysis   

       8.1.3 Financial analysis  

       8.1.4 Recent Developments       

       8.1.5 SWOT analysis       

       8.1.6 Analyst View          

                8.2 Acetylon Pharmaceuticals                    

                8.3 Celleron Therapeutics   

                8.4 Envivo Pharmaceuticals

                8.5 Novartis                       

                8.6 Merck & Co.      

                8.7 Pfizer   

                8.8 Eisai Pharmaceuticals    

9. Competitive Landscape                  

                9.1 Market share analysis   

                9.2 Merger and Acquisition Analysis                       

                9.3 Agreements, collaborations and Joint Ventures          

                9.4 New Product Launches

10. Market Outlook and Investment Opportunities                

Appendix                  

                a) List of Tables                

                b) List of Figures     

  • Global, regional and country-level analysis and forecasts of the study market; providing Insights on the major countries/regions in which this industry is blooming and to also identify the regions that are still untapped
  • The segment-level analysis in terms of product type by Application and Packaged Containers along with market size forecasts and estimations to detect key areas of industry growth in detail
  • Identification of key drivers, restraints, opportunities and challenges (DROC) in the market and their impact on shifting market dynamics
  • Study of the effect of exogenous and endogenous factors that affect the global market; which includes broadly demographic, economics, and political, among other macro-environmental factors presented in an extensive PESTLE Analysis
  • Study the micro environment factors that determine the overall profitability of an Industry, using Porter’s five forces analysis for analyzing the level of competition and business strategy development
  • A comprehensive list of key market players along with their product portfolio, current strategic interests, key financial information, legal issues, SWOT analysis and analyst overview to study and sustain the market environment
  • Competitive landscape analysis listing out the mergers, acquisitions, collaborations in the field along with new product launches, comparative financial studies and recent developments in the market by the major companies
  • An executive summary, abridging the entire report in such a way that decision-making personnel can rapidly become acquainted with background information, concise analysis and main conclusions
  • Expertly devised analyst overview along with Investment opportunities to provide both individuals and organizations a strong financial foothold in the market
  1. Global Histone Deacetylase Inhibitors Market By Region, From 2021 to 2026 ( USD Million )
  2. Global Histone Deacetylase Inhibitors Market By Application, From 2021 to 2026 ( USD Million )
  3. Global Cancer Market By Region, From 2021 to 2026 ( USD Million )
  4. Global Central Nervous System Disorders Market By Region, From 2021 to 2026 ( USD Million )
  5. Global Other Diseases Market By Region, From 2021 to 2026 ( USD Million )
  6. Global Histone Deacetylase Inhibitors Market By Class, From 2021 to 2026 ( USD Million )
  7. Global Class I HDACs Market By Region, From 2021 to 2026 ( USD Million )
  8. Global Class II HDACs Market By Region, From 2021 to 2026 ( USD Million )
  9. Global Class III HDACs Market By Region, From 2021 to 2026 ( USD Million )
  10. North America Histone Deacetylase Inhibitors Market By Application, From 2021 to 2026 ( USD Million )
  11. North America Cancer Market By Region, From 2021 to 2026 ( USD Million )
  12. North America Central Nervous System Disorders Market By Region, From 2021 to 2026 ( USD Million )
  13. North America Other Diseases Market By Region, From 2021 to 2026 ( USD Million )
  14. North America Histone Deacetylase Inhibitors Market By Class, From 2021 to 2026 ( USD Million )
  15. North America Class I HDACs Market By Region, From 2021 to 2026 ( USD Million )
  16. North America Class II HDACs Market By Region, From 2021 to 2026 ( USD Million )
  17. North America Class III HDACs Market By Region, From 2021 to 2026 ( USD Million )
  18. United States Histone Deacetylase Inhibitors Market By Application, From 2021 to 2026 ( USD Million )
  19. United States Histone Deacetylase Inhibitors Market By Class, From 2021 to 2026 ( USD Million )
  20. Canada Histone Deacetylase Inhibitors Market By Application, From 2021 to 2026 ( USD Million )
  21. Canada Histone Deacetylase Inhibitors Market By Class, From 2021 to 2026 ( USD Million )
  22. Europe Histone Deacetylase Inhibitors Market By Application, From 2021 to 2026 ( USD Million )
  23. Europe Cancer Market By Region, From 2021 to 2026 ( USD Million )
  24. Europe Central Nervous System Disorders Market By Region, From 2021 to 2026 ( USD Million )
  25. Europe Other Diseases Market By Region, From 2021 to 2026 ( USD Million )
  26. Europe Histone Deacetylase Inhibitors Market By Class, From 2021 to 2026 ( USD Million )
  27. Europe Class I HDACs Market By Region, From 2021 to 2026 ( USD Million )
  28. Europe Class II HDACs Market By Region, From 2021 to 2026 ( USD Million )
  29. Europe Class III HDACs Market By Region, From 2021 to 2026 ( USD Million )
  30. U.K. Histone Deacetylase Inhibitors Market By Application, From 2021 to 2026 ( USD Million )
  31. U.K. Histone Deacetylase Inhibitors Market By Class, From 2021 to 2026 ( USD Million )
  32. Germany Histone Deacetylase Inhibitors Market By Application, From 2021 to 2026 ( USD Million )
  33. Germany Histone Deacetylase Inhibitors Market By Class, From 2021 to 2026 ( USD Million )
  34. France Histone Deacetylase Inhibitors Market By Application, From 2021 to 2026 ( USD Million )
  35. France Histone Deacetylase Inhibitors Market By Class, From 2021 to 2026 ( USD Million )
  36. Italy Histone Deacetylase Inhibitors Market By Application, From 2021 to 2026 ( USD Million )
  37. Italy Histone Deacetylase Inhibitors Market By Class, From 2021 to 2026 ( USD Million )
  38. Spain Histone Deacetylase Inhibitors Market By Application, From 2021 to 2026 ( USD Million )
  39. Spain Histone Deacetylase Inhibitors Market By Class, From 2021 to 2026 ( USD Million )
  40. Asia Pacific Histone Deacetylase Inhibitors Market By Application, From 2021 to 2026 ( USD Million )
  41. Asia Pacific Cancer Market By Region, From 2021 to 2026 ( USD Million )
  42. Asia Pacific Central Nervous System Disorders Market By Region, From 2021 to 2026 ( USD Million )
  43. Asia Pacific Other Diseases Market By Region, From 2021 to 2026 ( USD Million )
  44. Asia Pacific Histone Deacetylase Inhibitors Market By Class, From 2021 to 2026 ( USD Million )
  45. Asia Pacific Class I HDACs Market By Region, From 2021 to 2026 ( USD Million )
  46. Asia Pacific Class II HDACs Market By Region, From 2021 to 2026 ( USD Million )
  47. Asia Pacific Class III HDACs Market By Region, From 2021 to 2026 ( USD Million )
  48. Japan Histone Deacetylase Inhibitors Market By Application, From 2021 to 2026 ( USD Million )
  49. Japan Histone Deacetylase Inhibitors Market By Class, From 2021 to 2026 ( USD Million )
  50. China Histone Deacetylase Inhibitors Market By Application, From 2021 to 2026 ( USD Million )
  51. China Histone Deacetylase Inhibitors Market By Class, From 2021 to 2026 ( USD Million )
  52. India Histone Deacetylase Inhibitors Market By Application, From 2021 to 2026 ( USD Million )
  53. India Histone Deacetylase Inhibitors Market By Class, From 2021 to 2026 ( USD Million )
  54. Australia Histone Deacetylase Inhibitors Market By Application, From 2021 to 2026 ( USD Million )
  55. Australia Histone Deacetylase Inhibitors Market By Class, From 2021 to 2026 ( USD Million )
  56. South Korea Histone Deacetylase Inhibitors Market By Application, From 2021 to 2026 ( USD Million )
  57. South Korea Histone Deacetylase Inhibitors Market By Class, From 2021 to 2026 ( USD Million )
  58. Latin America Histone Deacetylase Inhibitors Market By Application, From 2021 to 2026 ( USD Million )
  59. Latin America Cancer Market By Region, From 2021 to 2026 ( USD Million )
  60. Latin America Central Nervous System Disorders Market By Region, From 2021 to 2026 ( USD Million )
  61. Latin America Other Diseases Market By Region, From 2021 to 2026 ( USD Million )
  62. Latin America Histone Deacetylase Inhibitors Market By Class, From 2021 to 2026 ( USD Million )
  63. Latin America Class I HDACs Market By Region, From 2021 to 2026 ( USD Million )
  64. Latin America Class II HDACs Market By Region, From 2021 to 2026 ( USD Million )
  65. Latin America Class III HDACs Market By Region, From 2021 to 2026 ( USD Million )
  66. Brazil Histone Deacetylase Inhibitors Market By Application, From 2021 to 2026 ( USD Million )
  67. Brazil Histone Deacetylase Inhibitors Market By Class, From 2021 to 2026 ( USD Million )
  68. Argentina Histone Deacetylase Inhibitors Market By Application, From 2021 to 2026 ( USD Million )
  69. Argentina Histone Deacetylase Inhibitors Market By Class, From 2021 to 2026 ( USD Million )
  70. Mexico Histone Deacetylase Inhibitors Market By Application, From 2021 to 2026 ( USD Million )
  71. Mexico Histone Deacetylase Inhibitors Market By Class, From 2021 to 2026 ( USD Million )
  72. Rest of Latin America Histone Deacetylase Inhibitors Market By Application, From 2021 to 2026 ( USD Million )
  73. Rest of Latin America Histone Deacetylase Inhibitors Market By Class, From 2021 to 2026 ( USD Million )
  74. Middle East and Africa Histone Deacetylase Inhibitors Market By Application, From 2021 to 2026 ( USD Million )
  75. Middle East and Africa Cancer Market By Region, From 2021 to 2026 ( USD Million )
  76. Middle East and Africa Central Nervous System Disorders Market By Region, From 2021 to 2026 ( USD Million )
  77. Middle East and Africa Other Diseases Market By Region, From 2021 to 2026 ( USD Million )
  78. Middle East and Africa Histone Deacetylase Inhibitors Market By Class, From 2021 to 2026 ( USD Million )
  79. Middle East and Africa Class I HDACs Market By Region, From 2021 to 2026 ( USD Million )
  80. Middle East and Africa Class II HDACs Market By Region, From 2021 to 2026 ( USD Million )
  81. Middle East and Africa Class III HDACs Market By Region, From 2021 to 2026 ( USD Million )
  82. Middle East Histone Deacetylase Inhibitors Market By Application, From 2021 to 2026 ( USD Million )
  83. Middle East Histone Deacetylase Inhibitors Market By Class, From 2021 to 2026 ( USD Million )
  84. Africa Histone Deacetylase Inhibitors Market By Application, From 2021 to 2026 ( USD Million )
  85. Africa Histone Deacetylase Inhibitors Market By Class, From 2021 to 2026 ( USD Million )

Please wait. . . . Your request is being processed

Related Reports

LICENCE TYPE

$ 1234 4255

Clients
clients
clients
clients
clients
clients
clients
Click for Request Sample